Sankyo Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 135,000 million, operating profit of JPY 45,000 million, profit attributable to owners of parent JPY 35,000 million and basic earnings per share of JPY 602.71.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,623 JPY | +0.09% | -2.43% | -1.31% |
04-29 | AstraZeneca makes progress with Truqap and Enhertu cancer treatments | AN |
04-25 | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.31% | 2.33B | |
+13.21% | 8.4B | |
+9.43% | 693M | |
-28.66% | 674M | |
+31.17% | 380M | |
+4.63% | 339M | |
-0.83% | 336M | |
-11.45% | 258M | |
+6.00% | 172M | |
+27.47% | 103M |
- Stock Market
- Equities
- 6417 Stock
- News Sankyo Co., Ltd.
- Sankyo Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023